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Abstract
Background—Cognitive impairment is common in Parkinson’s disease (PD). There is a critical
need for a brief, standard cognitive screening measure for use in PD trials whose primary focus is
not on cognition.
Methods—The Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a
Task Force to make recommendations for a cognitive scale that could screen for dementia and
mild cognitive impairment in clinical trials of PD where cognition is not the primary outcome.
This Task Force conducted a systematic literature search for cognitive assessments previously
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used in a PD population. Scales were then evaluated for their appropriateness to screen for
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cognitive deficits in clinical trials, including brief administration time (<15 minutes), assessment
of the major cognitive domains, and potential to detect subtle cognitive impairment in PD.
Results—Five scales of global cognition met the predetermined screening criteria and were
considered for review. Based on the Task Force’s evaluation criteria the Montreal Cognitive
Assessment (MoCA), appeared to be the most suitable measure.
Conclusions—This Task Force recommends consideration of the MoCA as a minimum
cognitive screening measure in clinical trials of PD where cognitive performance is not the
primary outcome measure. The MoCA still requires further study of its diagnostic utility in PD
populations but appears to be the most appropriate measure among the currently available brief
cognitive assessments. Widespread adoption of a single instrument such as the MoCA in clinical
trials can improve comparability between research studies on PD.
INTRODUCTION
Cognitive impairment is common in Parkinson’s disease (PD), and it is estimated that the
majority of patients will develop dementia in the later stages of the disease.1 Considering
the high prevalence of cognitive impairment in PD and growing interest in the effects of
medical and surgical therapies on cognitive dysfunction and motor symptoms in this
population, there is a need for a brief cognitive test that can be consistently administered in
clinical trials of PD. Currently, individual researchers have their own preferences for
different cognitive tests, making it difficult to compare and cross-validate data between
studies.
Kulisevsky and Pagonabarraga recently conducted a systematic review of cognitive scales
used in PD,2 and identified the Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) as
the optimal PD-specific scale for detecting early cognitive deficits in PD and tracking the
transition to PD dementia. While this makes the PD-CRS suitable for clinical trials
investigating progression of cognitive dysfunction in PD, its administration time (17 minutes
in non-demented PD patients and 26 minutes in PDD patients)2 makes it less appropriate for
inclusion in clinical trials of PD not focused on cognition. Cognitive instruments used in
such trials need to be brief (e.g., < 15 minutes) for the purpose of screening large numbers of
participants for mild cognitive impairment and dementia, while allowing time for other
motor assessments that are the primary focus of the research.
To address the growing challenge of identifying cognitive dysfunction in PD clinical trials,
the Parkinson Study Group (PSG) Cognitive/Psychiatric Working Group formed a Task
Force to develop recommendations on a cognitive scale that could efficiently screen for both
dementia and mild cognitive impairment in treatment trials and other clinical research
investigations of PD where cognition is not the primary outcome.
METHODS
The Task Force includes 9 movement disorders neurologists, one cognitive neurologist, 4
neuropsychologists, and one psychiatrist. In order to guide selection and review of candidate
scales, the Task Force developed the following primary criteria (see Table): 1) the test must
have been previously studied in a PD population; 2) the test should be able to stand alone in
clinical trials, yet allow investigators to add additional cognitive assessments if indicated; 3)
administration should be completed within 15 minutes in order to minimize the burden of
testing in a patient undergoing a clinical trial; 4) all major cognitive domains (attention,
memory, language, visual-perception and construction, and executive functions) should be
assessed in order to screen for other causes of dementia, such as Alzheimer’s disease (AD),
5) the spectrum of cognitive impairment in PD, particularly subtle impairments involving
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executive functions, should be measured by the test or tests. If there were several scales that
met these 5 criteria, the Task Force considered the following secondary criteria in order to
narrow the choices to one scale for recommendation: 1) the tool should have been evaluated
in studies beyond those of its original developer, 2) psychometric performance data for PD
should be available.
Literature Search Strategy and Review of Tests
A systematic search was conducted of PUBMED (1950 to January 2009) using the search
terms “Cognitive Assessment” and “Parkinson’s disease” or “Parkinson disease” in the
English language literature for cognitive tests that had previously been used in a PD
population. 353 articles were retrieved and examined. In addition, in press peer-reviewed
papers or published abstracts known to the task force members were included.
After this critical review and discussion of the scales, a report was prepared by the members
of the Task Force and circulated to the Cognitive/Psychiatric Working Group for further
evaluation. A final draft, including the Group’s recommendations, was written and
submitted to the Executive Committee of the PSG for final approval before submission for
peer-review publication.
RESULTS
The literature search identified ten scales for consideration: Addenbrooke’s Cognitive
Evaluation (ACE),3 Alzheimer's Disease Assessment Scale—cognitive (ADAS-cog),4
Cambridge Cognitive Assessment (CAMCOG),5 Mattis Dementia Rating Scale (DRS),6
Mini-Mental Parkinson (MMP),7 Mini-Mental State Exam (MMSE),8 Montreal Cognitive
Assessment (MoCA),9 PD-CRS,10 Parkinson Neuropsychometric Dementia Assessment
(PANDA),11 and Scales for Outcomes in Parkinson’s disease–cognition (SCOPA-cog).12
Each instrument includes components that assess multiple cognitive domains, but the
summary scores provide measures of global cognitive function. Thus, each of these scales
could stand alone.
Five of the ten scales (ACE,3 ADAS-cog,13 CAMCOG,5,14 DRS,15 and PD-CRS10) were
excluded because administration time requires >15 minutes, leaving two generic
instruments, the MMSE and MoCA, and three PD-specific instruments, the MMP, PANDA,
and SCOPA-cog. The advantages and disadvantages of these 5 rating scales relative to the
rest of the evaluation criteria are summarized (Table).
Mini-Mental State Exam (MMSE)
The MMSE is the most widely used screening measure for detecting dementia. While not
developed specifically for PD patients, it is used consistently in PD studies and has the most
empiric evidence among the rating scales considered. Available in 58 languages, the MMSE
measures multiple cognitive domains on a 30-point scale: orientation (10 points),
registration and short-term recall (6-points), attention and concentration (5 points), language
(both oral and written) (8 points), and visuospatial function (1 point).8 It can be
administered within 10 minutes. The MMSE test manual and forms are owned and
copyrighted by Psychological Assessment Resources, Inc. (PAR). Alternate test versions of
the MMSE are available.
The MMSE has good test-retest and inter-rater reliability in the general population.16
However, it has not been specifically validated in the PD population. Although influenced
by age and education, age and education corrected normative data are available.17 A unique
advantage of the MMSE relative to the other scales discussed is that it can measure
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cognitive change over time in PD, especially in patients with dementia (about 2–2.5 points
per annum)18 and is sensitive to treatment effects in clinical trials.19,20
Despite its strengths, the MMSE does not measure the cognitive functions of reasoning,
planning, and set shifting (e.g. executive functions), which are commonly impaired in PD
patients early in the course of the disease.16,21 Furthermore, the naming task in the MMSE
has not been validated against formal naming tests (i.e. Boston Naming Test) and thus may
not detect a mild language deficit. Finally, the MMSE is relatively insensitive to mild
cognitive changes.9
Montreal Cognitive Assessment (MoCA)
The MoCA was originally developed to screen for mild cognitive impairment (MCI) in the
general population. Twenty-two language versions exist.9 It is free and may be used for
non-profit research with prior written permission. A licensing agreement is required if the
research is funded by a commercial entity. It is a 30-point test that can be administered in
about 10 minutes, but unlike the MMSE, the MoCA also covers a range of executive
functions. It has 6 orientation questions, and a 5 word memory recall task. A clock drawing
task and a cube copy test assess visuospatial function. Attention/concentration is assessed
using serial 7’s, target tapping, and digit span forward and backward. Confrontation naming
and repetition tasks assess language. Executive functions are evaluated using a shortened
version of the Trail Making B test, phonemic fluency, and a verbal abstraction task. In non-
PD samples, the MoCA has been shown to have excellent test-retest reliability and good
internal consistency in patients with (MCI).9
Four studies were identified that used the MoCA in PD populations,22–25 and all suggest
that the MoCA may be particularly sensitive to the mild cognitive changes seen in PD. The
MoCA has demonstrated good test-retest, inter-rater reliability, and convergent validity in
48 subjects with PD.22 A recent study in PD that compared the abilities of the MoCA and
MMSE to detect MCI and dementia compared to a neuropsychological battery reported that
the MoCA had acceptable sensitivity (0.82) and specificity (0.75) for dementia screening
using a cutoff of 24/25.25 For MCI screening in PD, the MoCA had acceptable sensitivity
(0.83), but low specificity (0.53) using a cutoff of 26/27, and the positive predictive (PPV)
and negative predictive values (NPV) for detecting MCI were not explicitly stated.25 The
PPV was poor (PPV 46% and NPV 92%) for the “diagnosis of any cognitive disorder” using
a 26/27 cutoff.
The main strengths of the MoCA are its rapid and easy administration, assessment of the
broad range of cognitive domains, and its sensitivity to milder cognitive deficits and
executive dysfunction in patients with PD. However, the naming task in the MoCA (3
animals) has not been properly validated and may not pick up mild language deficits. Cut-
off values for dementia and MCI are also not firmly established.
Mini-Mental Parkinson (MMP)
The MMP is a brief screening test derived from the MMSE and developed specifically to
assess cognition in PD.7 It is a 32-point test that takes approximately 10 minutes to
complete.26 Differences between the MMP and the MMSE include a time question on
orientation instead of the season, a visual registration task based on picture cards, a fluency
task where patients are asked to name 3 animals beginning with the same letter, visual
memory recall instead of verbal memory recall, a set-shifting task where subjects are given a
card with four images and asked to identify which image is different from the other 3, and a
concept processing (similarities) task wherein subjects are given 3 groups of 3 words and
asked which two words in each group are most closely related.
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In its validation study, the MMP was validated against a comprehensive neuropsychological
battery in 50 subjects with PD.7 The wide range of MMP total scores compared to the
MMSE suggests it may be more sensitive to detecting the mild cognitive deficits seen in PD.
Content validity and construct validity was assessed and inter-rater reliability was high
(r=0.84), but no other psychometric properties were assessed.7 Despite being developed
specifically for PD, the MMP has been evaluated in only one other study.26
Advantages of the MMP include quick administration time and potential to detect early
cognitive changes in PD. However, the MMP is still heavily weighted towards orientation,
does not assess other cortically mediated functions such as language, and has limited data
regarding psychometric performance in PD.
Parkinson Neuropsychometric Dementia Assessment (PANDA)
The PANDA was developed to be a brief assessment (~10 minutes) to detect subtle
cognitive impairment and dementia in patients with PD in research and clinical care settings.
11 Four cognitive domains are tested: memory (verbal paired associate learning), executive
functioning (alternating categorical fluency), visuospatial abilities (visual imagery), and
working memory/attention (number sequencing). A fifth section screens for depressive
symptoms (mood, interest, and drive).
Only two studies have used the PANDA in PD but initial data suggest that it is a reliable
tool that is more sensitive than the MMSE for detecting cognitive impairment in patients
with PD.11,27 Test-retest reliability is high (r=.93), as is inter-rater reliability (r=.95).11
While sensitivity, specificity, and cut-off scores for dementia and MCI have been published,
they are not firmly established. Moreover, the PANDA does not assess orientation,
language, or visual construction.
Scales for Outcomes in Parkinson’s disease-cognition (SCOPA-cog)
SCOPA-cog is a PD-specific scale that was developed for the purpose of comparing groups
in research settings, not as a screening or diagnostic tool.12 It is available without
restrictions for use in research. The instrument consists of 10 items, with a maximum score
of 43, and can be administered in approximately 10–15 minutes. Non-verbal and verbal
memory and learning are assessed using a cube test (copying the order in which 4 cubes are
pointed), backward digit span, and reading/recalling 10 words. Attention is assessed by
saying the months backward and serial three subtractions. Aspects of executive functions
measured include: complex motor planning, working memory, and verbal fluency. A figure
assembly task to assess visuospatial function completes the scale. The SCOPA-cog is
available in Dutch, English and Portuguese (Brazilian) versions.12,28,29
The inclusion of specific tasks of executive function make the SCOPA-cog more likely to be
sensitive to early cognitive changes in the PD population than the MMSE.12 In its validation
study, the SCOPA-cog was validated against the CAMCOG and had higher reproducibility
than the MMSE (0.78 vs. 0.66) and greater internal consistency than the MMSE (0.83 vs.
0.62).12 Although SCOPA-cog was developed specifically for a PD population, it has not
been used extensively in PD.2 Despite the SCOPA-cog’s potential sensitivity to early
cognitive changes in PD it has not been evaluated in PD patients with diagnoses of MCI or
dementia to be able to determine sensitivity, specificity, or cut-off values and it does not
measure orientation and language function.
CONCLUSIONS AND RECOMMENDATIONS
The purpose of this review was to identify and recommend a brief, standard cognitive
measure that could be used to screen PD subjects for dementia and cognitive impairment in
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research studies where cognitive performance is not the primary outcome measure. Of the 5
instruments reviewed, only the MoCA fulfilled the primary criteria established by the Task
Force. Thus, the Task Force preliminarily recommends the MoCA as a minimum standard
cognitive screening instrument in clinical trials of PD. It can be administered rapidly and has
the potential to identify subtle executive dysfunction while also covering the major cognitive
domains.
All available instruments that can be briefly administered have limitations. The MMSE has
been used extensively in studies of patients with PD, can measure progression once patients
develop dementia, and is sensitive to change in clinical trials. However, its deficiencies
include a distinct ceiling effect and its inability to assess executive functions. Therefore, it is
unlikely to detect MCI in PD, a primary concern if the instrument is to serve as a screening
measure for mild cognitive dysfunction. While the MoCA, MMP, PANDA, and SCOPA-cog
all appear suitable for detecting early cognitive dysfunction in PD, each has undergone
limited cross-validation in PD samples. Some instruments (MoCA and MMSE) include
language tasks, but do not assess this domain as adequately as longer and more
comprehensive assessments. While all of the scales included in this review can be
administered in less than 15 minutes, published administration times are likely based on
non-demented populations and may take longer in demented PD participants.
Although preliminary data seems to suggest that the MoCA may be a poor screening
measure for MCI in PD based on its reported low specificity (0.53) using a cutoff of
26/27,25 this study had several flaws that limit the strength of the conclusions that can be
made regarding its utility to detect MCI. The diagnostic criteria for defining MCI has not
been well established in PD and the requirement of self-reported cognitive decline in this
study25 may require a degree of insight not commonly seen in patients with a
neurodegenerative process affecting frontally-mediated functions such as meta-cognition.
Additionally, the study had small numbers of subjects with cognitive impairment (only
12.9% PDD and 17.4% MCI out of 132 subjects), and a limited neuropsychological battery
was used.25
A brief scale for screening dementia in PD (PDD-Short Screen) was recently published,30
which took 4.8–6.9 minutes to administer and had high sensitivity (0.898) and specificity
(0.885) for diagnosing PDD. Unfortunately, it may not be sensitive enough to detect subtle
executive dysfunction in PD and thus did not meet our Task Force’s objectives.
The aim of this Task Force is complementary yet distinguishable from a recent review by
Kulisevsky and Pagonabarraga that evaluated different instruments on their appropriateness
to assess cognition throughout the course of PD.2 That review identified both SCOPA-cog
and PD-CRS as the most appropriate for capturing early PD cognitive changes and PD-CRS
as the most suitable for monitoring cognitive progression in PD. However, SCOPA-cog does
not measure orientation or language function, which would be useful in a screening measure
to rule out alternative causes for dementia, such as AD. The lengthier administration time of
the PD-CRS precludes its use as a screening instrument in clinical trials of PD not focusing
primarily on cognition. Our review is also different from the recent efforts of a Movement
Disorders Society (MDS) Task Force on Dementia in Parkinson’s Disease that established
diagnostic criteria for dementia in PD31 as well as a practical approach to its diagnosis.32
Should the MoCA be utilized in clinical trials going forward, the dilemma of how to
compare new data to existing trials that used the MMSE needs to be addressed. A potential
strategy would be to transform MMSE and MoCA scores into equivalent z-scores,17 which
would allow comparison of cognitive performance between the two groups. However, the
absence of age and education normative data for the MoCA limits this practice. For now, the
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most parsimonious strategy would be to administer both the MoCA and the MMSE until
further evidence is available to demonstrate whether it is an appropriate tool. For existing
clinical trial databases that have extensive MMSE data only, using age and education
adjusted MMSE cut-offs for cognitive impairment may be helpful. In a recent study on
cognitive impairment in the DATATOP study cohort,33 Uc et al. found that subjects who
developed cognitive impairment by age and education adjusted MMSE criteria showed
significant decline on neuropsychological tests while the neuropsychological performance of
non-impaired subjects remained stable.
This task force recommends consideration of the MoCA as a screening instrument for
dementia and MCI in PD clinical studies where cognition is not the primary outcome
measure. Widespread adoption of such an instrument in clinical trials will improve
comparability among research studies on motor and non-motor aspects of PD. The MoCA
still requires further study of its validity in PD populations to determine how well it detects
MCI and dementia, and it could also benefit from the development of age and education
normative data. Despite these flaws, the MoCA shows the most promise of the currently
available brief cognitive assessments. Since the MoCA lacks data regarding sensitivity to
change over time and to treatment, the Task Force does not recommend use of the MoCA as
a stand-alone measure in PD trials investigating progression of cognitive impairment. If
future evidence demonstrates that the MoCA is sensitive to longitudinal treatment effects
and cognitive decline, then the MoCA may be considered for use as a primary outcome
measure.
Acknowledgments
The authors thank the anonymous reviewer(s) for their thoughtful, detailed and constructive comments of our
paper.
REFERENCES
1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of
Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008; 23(6):837–844.
[PubMed: 18307261]
2. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and
assessment. Mov Disord. 2009; 24(8):1103–1110. [PubMed: 19353727]
3. Reyes MA, Lloret SP, Gerscovich ER, Martin ME, Leiguarda R, Merello M. Addenbrooke's
Cognitive Examination validation in Parkinson's disease. Eur J Neurol. 2009; 16(1):142–147.
[PubMed: 19049504]
4. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement,
rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994; 151(3):390–396. [PubMed:
8109647]
5. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population
of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age
Ageing. 1999; 28(1):39–43. [PubMed: 10203203]
6. Mattis, S. Dementia Rating Scale professonal manual. Odessa, FL: Psychological Assessment
Resources; 1988.
7. Mahieux F, Michelet D, Manifacier M-J, Boller F, Fermanian J, Guillard A. Mini-Mental Parkinson:
first validation study of a new bedside test constructed for Parkinson's disease. Behavioural
Neurology. 1995; 8:15–22.
8. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the
cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189–198. [PubMed:
1202204]
Chou et al. Page 8













9. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief
screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695–699. [PubMed:
15817019]
10. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A.
Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease.
Mov Disord. 2008; 23(7):998–1005. [PubMed: 18381647]
11. Kalbe E, Calabrese P, Kohn N, et al. Screening for cognitive deficits in Parkinson's disease with
the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat
Disord. 2008; 14(2):93–101. [PubMed: 17707678]
12. Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson's disease.
Neurology. 2003; 61(9):1222–1228. [PubMed: 14610124]
13. Ferris SH. Cognitive outcome measures. Alzheimer Dis Assoc Disord. 1999; 13 Suppl 3:S140–
S142. [PubMed: 10609693]
14. Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community
population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised
(CAMCOG-R). Age Ageing. 2005; 34(3):268–273. [PubMed: 15863411]
15. Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the Mattis Dementia Rating
Scale for screening dementia in Parkinson's disease. Mov Disord. 2008; 23(11):1546–1550.
[PubMed: 18546326]
16. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am
Geriatr Soc. 1992; 40(9):922–935. [PubMed: 1512391]
17. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental
State Examination by age and educational level. Jama. 1993; 269(18):2386–2391. [PubMed:
8479064]
18. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch
Neurol. 2004; 61(12):1906–1911. [PubMed: 15596611]
19. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's
disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002; 72(6):708–712.
[PubMed: 12023410]
20. Muller T, Welnic J, Fuchs G, Baas H, Ebersbach G, Reichmann H. The DONPAD-study--
treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl.
2006; (71):27–30. [PubMed: 17447412]
21. Wind AW, Schellevis FG, Van Staveren G, Scholten RP, Jonker C, Van Eijk JT. Limitations of the
Mini-Mental State Examination in diagnosing dementia in general practice. Int J Geriatr
Psychiatry. 1997; 12(1):101–108. [PubMed: 9050431]
22. Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening
tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008; 23(7):1043–1046.
[PubMed: 18381646]
23. Zadikoff C, Fox SH, Tang-Wai DF, et al. A comparison of the mini mental state exam to the
Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov
Disord. 2008; 23(2):297–299. [PubMed: 18044697]
24. Nazem S, Siderowf AD, Duda JE, et al. Montreal cognitive assessment performance in patients
with Parkinson's disease with "normal" global cognition according to mini-mental state
examination score. J Am Geriatr Soc. 2009; 57(2):304–308. [PubMed: 19170786]
25. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI
and dementia in Parkinson disease. Neurology. 2009; 73(21):1738–1745. [PubMed: 19933974]
26. Di Virgilio G, Leroy A, Cunin P, Mahieux F, Bachoud-Levi A-C, Fenelon G. The Mini Mental
Parkinson brief cognitive test: Comparison with the Mattis dementia rating scale in 289 patients
with Parkinson's disease. Mov Disord. 2007; 22 Suppl 16:S89–S90.
27. Riedel O, Klotsche J, Spottke A, et al. Cognitive impairment in 873 patients with idiopathic
Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with
Dementia (GEPAD). J Neurol. 2008; 255(2):255–264. [PubMed: 18204803]
28. Carod-Artal FJ, Martinez-Martin P, Kummer W, Ribeiro Lda S. Psychometric attributes of the
SCOPA-COG Brazilian version. Mov Disord. 2008; 23(1):81–87. [PubMed: 17987646]
Chou et al. Page 9













29. Verbaan D, Marinus J, Visser M, et al. Cognitive impairment in Parkinson's disease. J Neurol
Neurosurg Psychiatry. 2007; 78(11):1182–1187. [PubMed: 17442759]
30. Pagonabarraga J, Kulisevsky J, Llebaria G, et al. PDD-Short Screen: a brief cognitive test for
screening dementia in Parkinson's disease. Mov Disord. 2010; 25(4):440–446. [PubMed:
20155863]
31. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with
Parkinson's disease. Mov Disord. 2007; 22(12):1689–1707. quiz 1837. [PubMed: 17542011]
32. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia:
recommendations from the movement disorder society task force. Mov Disord. 2007; 22(16):
2314–2324. [PubMed: 18098298]
33. Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment
in an early Parkinson disease clinical trial cohort. Neurology. 2009; 73(18):1469–1477. [PubMed:
19884574]
Chou et al. Page 10





































































































































































































































































































Mov Disord. Author manuscript; available in PMC 2011 November 15.
